Liraglutide as Additional T t t i T 1 Di b tTreatment in Type 1 Diabetes

Ajay Varanasi, Natalie Bellini, Deepti Rawal, Mehul Vora, AntoineMakdissi, Sandeep Dhindsa, Ajay Chaudhuri and

P h D dParesh Dandona

Division of Endocrinology Diabetes and MetabolismDivision of Endocrinology, Diabetes and Metabolism, State University of New York at Buffalo

"J.L." before insulin on December 7, 1922 (15 pounds) and after insulin on February 26, 1923 (30 pounds).

*

Incretin Effect*

**

* **

*

St d dStandard Deviation decreased

average of 20 gmg/dl

1) DFPre-VictozaHBA1C = 7.4

On Victoza

Post Victoza

The Pathogenesis of Type 2 DiabetesThe Pathogenesis of Type 2 DiabetesBetaBeta--Cell Workload Outpaces BetaCell Workload Outpaces Beta--Cell ResponseCell ResponseThe Pathogenesis of Type 2 DiabetesThe Pathogenesis of Type 2 DiabetesBetaBeta--Cell Workload Outpaces BetaCell Workload Outpaces Beta--Cell ResponseCell Response

Healthy Subjects (n = 14)

Beta-CellWorkload Beta-CellWorkload

Type 2 Diabetes (n = 12)

Beta-CellWorkload Beta-CellWorkload

Carbohydrate Meal

Beta-CellResponse Beta-CellResponse

WorkloadWorkload

Beta-CellResponse Beta-CellResponse

WorkloadWorkload

Beta-Cell Beta-Cell

ResponseResponse

Beta-Cell Beta-Cell

ResponseResponse

Beta-CellWorkload Beta-CellWorkload Beta-CellWorkload Beta-CellWorkload

EuglycemiaEuglycemiaEuglycemiaEuglycemiaHyperglycemiaHyperglycemia

Mean (SE)

3) KGPre Vi tVictozaA1C 6.5

O Vi tOn Victoza